# reload+after+2024-01-20 15:44:19.579772
address1§Clarendon House
address2§2 Church Street
city§Hamilton
zip§HM 11
country§Bermuda
phone§441 295 5950
website§https://altamiratherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is headquartered in Hamilton, Bermuda.
fullTimeEmployees§16
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Thomas  Meyer Ph.D.', 'age': 55, 'title': 'Founder, Chairman, CEO & MD', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 592050, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Marcel  Gremaud CPA', 'age': 65, 'title': 'Chief Financial Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Covadonga  Paneda', 'age': 49, 'title': 'Chief Operating Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Samuel A. Wickline M.D.', 'age': 70, 'title': 'Chief Scientific Adviser', 'yearBorn': 1953, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.428
priceToSalesTrailing12Months§36.775364
currency§USD
dateShortInterest§1702598400
exchange§NCM
quoteType§EQUITY
shortName§Altamira Therapeutics Ltd.
longName§Altamira Therapeutics Ltd.
firstTradeDateEpochUtc§1407331800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§73e41d6d-d768-3dba-b766-fc7bbc4c1528
gmtOffSetMilliseconds§-18000000
recommendationKey§none
quickRatio§0.156
grossMargins§-2.85581
ebitdaMargins§0.0
trailingPegRatio§None
